Linked Life Data

2544286

Source:http://linkedlifedata.com/resource/pubmed/id/2544286

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-7-28
pubmed:abstractText
The novel 5-HT 1-like receptor agonist GR43175 has been evaluated as a treatment for acute migraine in a series of open, dose-ranging and controlled clinical trials. Patients with severe attacks of migraine have attended special pain or headache clinics for treatment and assessment. Given intravenously as a bolus, GR43175 is capable of aborting all migraine symptoms within 10-30 min in over 90% of cases at a dose of 64 micrograms/kg. Characteristic transient and reversible side effects with such a regimen include feelings of heaviness, pressure and occasionally warmth or tingling which can be diminished by extending the duration of drug administration to a short infusion. Initial dose-ranging studies with a dispersible tablet formulation of GR43175 have revealed an efficacy of 70-85% within 2 h with doses of 70-280 mg. Furthermore, tolerability is excellent. These encouraging early results warrant larger-scale controlled studies of GR43175 in acute migraine.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0333-1024
pubmed:author
pubmed:issnType
Print
pubmed:volume
9 Suppl 9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
63-72
pubmed:dateRevised
2008-2-11
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine.
pubmed:affiliation
Medical Division, Glaxo Group Research Limited, Greenford, Middlesex, UK.
pubmed:publicationType
Journal Article